Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson – biolegacy

Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson

Post author:Sam
Post published:February 8, 2018
Post category:BioPharma

Syndesi will work to modulate the synaptic vesicle protein SV2A.
Source: BioSpace